2 news items
Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
COCP
13 May 24
in a randomized, double-blind, dose-escalating Phase 1 study to evaluate the safety, tolerability and pharmacokinetics (PK) of oral CC-42344 in healthy
Cocrystal Pharma Receives Pre-IND Responses From The FDA On Oral CC-42344 For Treating Influenza A
COCP
19 Mar 24
planned oral CC-42344 clinical program."A Phase 2a challenge study of oral CC-42344 is underway in the United Kingdom to evaluate safety, and viral
- Prev
- 1
- Next